|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification |
| Gerhardt Attard, MD, PhD, FRCP |
| Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| Systematic Review Sheds Light on Treatment Intensification in Metastatic Prostate Cancer |
Peter Goebell, MD, PhD
Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell's study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. |
|
|
|
|
|
|
|
|
|
|
| AR Pathway Inhibitors vs Taxanes in mCRPC ProBio Trial |
| Bram De Laere, PhD |
| Bram De Laere discusses the ProBio trial, a platform study for metastatic prostate cancer. Dr. De Laere explains the trial's unique design, which uses circulating tumor DNA analysis to guide treatment decisions and evaluate multiple biomarker-therapy combinations simultaneously. |
|
|
|
|
|
|
|
|
|
|
|
| Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer
|
| Neil Desai, MD
|
| Neil Desai highlighted advanced tools for managing unfavorable intermediate-risk prostate cancer, focusing on ADT and genomic risk stratification. He discussed the role of risk classifiers, such as mRNA-based tests (Decipher, Prolaris, Oncotype DX) and multi-modal AI models, in personalizing ADT use and guiding radiation therapy intensity. For patients with low genomic risk, RT alone may be sufficient, while those with high-risk scores benefit more from intensified ADT and RT.
|
|
|
|
|
|
| A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)
|
| Kosj Yamoah, MD, PhD
|
| Kosj Yamoah presented the VANDAAM Study, which validated the Decipher® genomic risk classifier’s utility in African American and non-African American men with prostate cancer. This study addressed an important gap in data by prospectively validating Decipher® in African American men, a group that faces a higher burden of prostate cancer.
|
|
|
|
|
|
| Impact of Time to Metastatic Disease Onset and Extent of Disease Volume Across Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer - Beyond the Abstract
|
| Mike Wenzel, Benedikt Hoeh, Philipp Kopf et al.
|
| This study, utilizing the FRAMCAP database, explored how the timing and volume of metastatic disease affect clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Patients with de novo high-volume (DNHV) mHSPC had the shortest time to castration resistance (median 15 months) and overall survival (median 44 months), indicating a poorer prognosis, while those with metachronous low-volume (SecLV) mHSPC had the most favorable outcomes, with a median OS of 120 months.
|
|
|
|
|
|
| UpFrontPSMA : A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer |
| Arun Azad, PhD, MBBS, FRACP |
| Arun Azad presented results from the UpFrontPSMA trial, which showed that adding 177Lu-PSMA-617 to docetaxel improved undetectable PSA rates at 48 weeks in high-volume metastatic hormone-sensitive prostate cancer patients compared to docetaxel alone. The combination therapy also extended PSA progression-free survival and delayed castration resistance without increasing overall toxicity. |
|
|
|
|
|
|
|
|
|
|
| Validation of a Digital Pathology-Based MMAI Model in Oligometastatic Castration-Sensitive Prostate Cancer, including Patients from the STOMP and ORIOLE Phase II Randomized Trial
|
| Philip Sutera, MD
|
| Philip Sutera presented the validation of the ArteraAI Prostate Test, a digital pathology-based multimodal AI (MMAI) biomarker, in oligometastatic castration-sensitive prostate cancer (mCSPC). This MMAI biomarker, previously validated for localized prostate cancer, was tested in 222 patients with oligometastatic mCSPC to assess its prognostic value for overall survival and its predictive ability for the benefit of metastasis-directed therapy.
|
|
|
|
|
|
| Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial - Beyond the Abstract |
| Maria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando et al. |
| The PRESIDE Phase 3b trial biomarker study explored the role of liquid biopsy in mCRPC patients starting docetaxel with or without enzalutamide. Findings showed that patients with detectable ctDNA before starting docetaxel had shorter progression-free survival and those with a persistent increase in ctDNA after the first cycle of treatment experienced earlier progression. |
|
|
|
|
|
|
|
|
|
|
